Novartis shares plunge 12.5% after two Phase 3 drug trials fail primary goals

Novartis shares dropped over 12.5% after its Phase 3 HARBOR trial for del-desiran and Phase 3 HORIZON trial for pelacarsen both failed to meet primary endpoints. These failures mean the drugs did not show significant benefits over placebo for their targeted conditions, impacting investor confidence. A securities law investigation has been launched to examine if Novartis made misleading statements about these drug programs. Investors who suffered losses are encouraged to review their options with legal counsel.